Irlanda - anglès - HPRA (Health Products Regulatory Authority)

medac gesellschaft fur klinische spezialpraparate - oxaliplatin - pdr for soln for infusion - 5 mg/ml

Irlanda - anglès - HPRA (Health Products Regulatory Authority)

medac gesellschaft fur klinische spezialpraparate - folinic acid - solution for injection - 50 mg/ml

Irlanda - anglès - HPRA (Health Products Regulatory Authority)

medac gesellschaft fur klinische spezialpraparate - folinic acid - solution for injection - 50 mg/ml

Israel - anglès - Ministry of Health

tzamal bio-pharma ltd - gemcitabine as hydrochloride - powder for solution for infusion - gemcitabine as hydrochloride 200 mg - gemcitabine - gemcitabine - palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locally advanced or metastatic adenocarcinoma of the pancreas and for patients with 5-fu refractory pancreatic cancer. gemcitabine is indicated for the treatment of patients with bladder cancer at the invasive stage. breast cancer: gemcitabine in combination with paclitaxel is indicated for the treatment of patients with unresectable locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. ovarian cancer: gemcitabine in combination with carboplatin is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma whom have relapsed at least six months after platinum - based therapy.

Israel - anglès - Ministry of Health

tzamal bio-pharma ltd - gemcitabine as hydrochloride - powder for solution for infusion - gemcitabine as hydrochloride 1000 mg - gemcitabine - gemcitabine - palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locally advanced or metastatic adenocarcinoma of the pancreas and for patients with 5-fu refractory pancreatic cancer.gemcitabine is indicated for the treatment of patients with bladder cancer at the invasive stage. breast cancer: gemcitabine in combination with paclitaxel is indicated for the treatment of patients with unresectable locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. ovarian cancer: gemcitabine in combination with carboplatin is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma whom have relapsed at least six months after platinum - based therapy.

Irlanda - anglès - HPRA (Health Products Regulatory Authority)

medac gesellschaft fur klinische spezialpraparate - treosulfan - capsule - 250 mg milligram

Irlanda - anglès - HPRA (Health Products Regulatory Authority)

medac gesellschaft fur klinische spezialpraparate - treosulfan - capsule - 250 mg milligram

Israel - anglès - Ministry of Health

tzamal bio-pharma ltd - 5-aminolevulinic acid as hydrochloride - powder for solution - 5-aminolevulinic acid as hydrochloride 1.5 g - aminolevulinic acid - aminolevulinic acid - gliolan® is indicated in adult patients for visualisation of malignant tissue during surgery for malignant glioma (who grade iii and iv).

Regne Unit - anglès - MHRA (Medicines & Healthcare Products Regulatory Agency)

medac uk - treosulfan - oral capsule - 250mg

Unió Europea - anglès - EMA (European Medicines Agency)

medac gesellschaft fuer klinische spezialpraeparate mbh - asparaginase - precursor cell lymphoblastic leukemia-lymphoma - antineoplastic agents - spectrila is indicated as a component of antineoplastic combination therapy for the treatment of acute lymphoblastic leukaemia (all) in paediatric patients from birth to 18 years and adults.